iRay Group

iRay Group Equity

The The Equity of iRay Group (688301.SS) as of Oct 19, 2026 is 6.07 B CNY. In the previous year, The Equity was 4.64 B CNY — a change of 30.88% (higher).

Equity

6.07 BCNY

YoY

30.88%

Last updated:

In 2025, iRay Group's equity was 6.07 B CNY, a 30.88% increase from the 4.64 B CNY equity in the previous year.

The iRay Group Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
329.51 M CNY
Jan 1, 2019
425.54 M CNY
Jan 1, 2020
2.63 B CNY
Jan 1, 2021
3.05 B CNY
Jan 1, 2022
3.88 B CNY
Jan 1, 2023
4.33 B CNY
Jan 1, 2024
4.64 B CNY
Jan 1, 2025
6.07 B CNY
The iRay Group Equity history
YEAREquityYoY
6.07 BCNY+30.88%
4.64 BCNY+7.12%
4.33 BCNY+11.70%
3.88 BCNY+27.01%
3.05 BCNY+15.90%
2.63 BCNY+518.87%
425.54 MCNY+29.14%
329.51 MCNY+31.12%
251.31 MCNY+41.43%
177.70 MCNY+31.70%
134.92 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iRay Group Stock analysis

What does iRay Group do? iRay Group, operating under the ticker symbol 688301.SS and identified by ISIN CNE1000042V8, is a prominent entity within the Chinese healthcare sector. Headquartered in Shanghai, the company has established itself as a significant player in the medical technology industry, specifically focusing on the development and manufacturing of advanced digital imaging solutions. The organization went public on September 18, 2020, marking a pivotal moment in its corporate history and allowing it to expand its operational capabilities on a broader scale. As of the latest available data, iRay Group employs a workforce of 1,237 full-time employees, reflecting its substantial operational footprint and commitment to human capital in driving technological innovation. The core business of the company revolves around the research, development, production, and sale of digital X-ray detectors, which are critical components in modern medical diagnostic equipment. These detectors are engineered to provide high-resolution imaging, enabling healthcare professionals to make accurate and timely diagnoses. The product portfolio of iRay Group is diverse and tailored to meet various clinical and industrial needs. Key product lines include the universal radio frequency series, which offers versatile imaging solutions for general diagnostic purposes. Additionally, the company manufactures specialized breast series detectors designed specifically for mammography, ensuring high sensitivity and image clarity for early detection of breast abnormalities. The radiotherapy series further expands the company's reach into therapeutic applications, providing essential imaging support for radiation treatment planning and monitoring. Beyond the medical sector, the technology developed by iRay Group finds application in industrial non-destructive testing and security inspection fields. This diversification highlights the robustness of their detector technology, which can be adapted for inspecting materials integrity in manufacturing or screening for security threats. The company maintains a comprehensive distribution network that serves both the domestic market within China and international markets overseas. This global reach underscores the competitive quality of their products and the company's strategic focus on expanding its presence in the worldwide healthcare and industrial technology sectors. By leveraging its expertise in digital X-ray technology, iRay Group continues to contribute to advancements in medical diagnostics and industrial safety, positioning itself as a key innovator in the health care industry. iRay Group is one of the most popular companies on Eulerpool.

Equity Details

Analyzing iRay Group's Equity

iRay Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding iRay Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating iRay Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

iRay Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in iRay Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about iRay Group stock

The Equity of iRay Group is 6.07 B CNY in 2025.

The Equity of iRay Group changed from 4.64 B CNY to 6.07 B CNY, representing a 30.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity iRay Group since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's iRay Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — iRay Group

All Key Metrics — iRay Group